Abstract:

Objective   To investigate the prognostic values of matrix metalloproteinase 9 (MMP-9) in predicting unstable angina pectoris (UAP) after the PCI(Percutaneious coronary intervention) treatment. Methods   A total of 136 patients with UAP were treated with PCI. Blood samples were collected pre- and postoperatively. Enzyme-linked immunosorbent assay was used to detect MMP-9. We recorded important adverse cardiac events (MACE) in 6-month follow-up. Results   MMP-9 concentration dropped after the operation (preoperative 15.9 ± 2.5 ng / mL vs postoperative 10.9±2.3ng / mL, t=17.165, P=0.000). The average MMP-9 decrease rate was 31.4%. Within six-month follow-up, 19 patients had MACE (14.0%). Postoperative MMP-9 concentration in MACE patients was higher than those without MACE (13.9 ± 2.5ng / mL vs 10.5 ± 2.4ng / mL, t=11.441, P=0.000). The area under the ROC curve of MMP-9 decrease rate to predict MACE was 0.723, 95% CI of 0.624-0.754. If the cutoff was set at 15%, the specificity was 78.5%, while the sensitivity was 82.1%. Prognostic analysis showed that incidence of MACE in the group with MMP-9 decreased rate not above 15% was higher than those on the contrary (χ2=2.579, P=0.038). Adjusted by Cox multivariate, OR for the occurrence of MACE was 1.454 (≤15% vs>15%). Conclusion   Matrix metalloproteinase-9 can predict the prognosis for unstable angina pectoris after percutaneous coronary intervention. When the decreasing rate of MMP-9 is below 15%, more attention should be paid for the occurrence of major adverse cardiac events.

Key words: Unstable Angina Pectoris; Percutaneous Coronary Intervention; Matrix Metalloproteinase-9; Prognosis